M
Maarten de Wit
Researcher at University of Amsterdam
Publications - 181
Citations - 14146
Maarten de Wit is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Psoriatic arthritis & Medicine. The author has an hindex of 36, co-authored 149 publications receiving 11252 citations. Previous affiliations of Maarten de Wit include Royal Prince Alfred Hospital & Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update
Josef S Smolen,Robert Landewé,Ferdinand C. Breedveld,Maya H Buch,Maya H Buch,Gerd R Burmester,Maxime Dougados,Paul Emery,Paul Emery,Cécile Gaujoux-Viala,Laure Gossec,Jackie L Nam,Jackie L Nam,Sofia Ramiro,Kevin L. Winthrop,Maarten de Wit,Daniel Aletaha,Neil Betteridge,Johannes W. J. Bijlsma,Maarten Boers,Frank Buttgereit,Bernard Combe,Maurizio Cutolo,Nemanja Damjanov,Johanna M. W. Hazes,Marios Kouloumas,Tore K Kvien,Xavier Mariette,Karel Pavelka,Piet L. C. M. van Riel,Andrea Rubbert-Roth,Marieke Scholte-Voshaar,David Scott,T. Sokka-Isler,John B. Wong,Désirée van der Heijde +35 more
TL;DR: These recommendations intend informing rheumatologists, patients, national rheumology societies, hospital officials, social security agencies and regulators about EULAR's most recent consensus on the management of RA, aimed at attaining best outcomes with current therapies.
Journal ArticleDOI
Treating rheumatoid arthritis to target: recommendations of an international task force
Josef S Smolen,Daniel Aletaha,J. Bijlsma,Ferdinand C. Breedveld,Dimitrios T. Boumpas,Gerd R Burmester,Bernard Combe,Maurizio Cutolo,Maarten de Wit,Maxime Dougados,Paul Emery,A. Gibofsky,Juan J. Gomez-Reino,Boulos Haraoui,Joachim Kalden,Edward C. Keystone,Tore K Kvien,Iain B. McInnes,Emilio Martín-Mola,Carlomaurizio Montecucco,Monika Schoels,Désirée van der Heijde +21 more
TL;DR: The 10 recommendations are supposed to inform patients, rheumatologists and other stakeholders about strategies to reach optimal outcomes of RA based on evidence and expert opinion.
Journal ArticleDOI
American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials
David T. Felson,David T. Felson,Josef S Smolen,George A. Wells,Bi Zhang,Lilian H D van Tuyl,Julia Funovits,Daniel Aletaha,Cornelia F Allaart,Joan M. Bathon,Joan M. Bathon,Stefano Bombardieri,Peter Brooks,Andrew K Brown,Marco Matucci-Cerinic,Hyon K. Choi,Bernard Combe,Maarten de Wit,Maxime Dougados,Paul Emery,Daniel E. Furst,Juan J. Gomez-Reino,Gillian A. Hawker,Edward C. Keystone,Dinesh Khanna,John R. Kirwan,Tore K Kvien,Robert Landewé,Joachim Listing,Kaleb Michaud,Emilio Martín-Mola,Pamela Montie,Theodore Pincus,Pamela Richards,Jeffrey Siegel,Jeffrey Siegel,Lee S. Simon,Tuulikki Sokka,Vibeke Strand,Peter Tugwell,Alan Tyndall,Désirée van der Heijde,S. M. M. Verstappen,Barbara White,Frederick Wolfe,Angela Zink,Maarten Boers +46 more
TL;DR: It is proposed that a patient's RA can be defined as being in remission based on one of two definitions: (1) when scores on the tender joint count, swollen joint counts, CRP level, and patient global assessment are all ≤1, or (2) when the score on the Simplified Disease Activity Index is ≤3.
Journal ArticleDOI
EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update
Laure Gossec,Xenofon Baraliakos,Andreas Kerschbaumer,Maarten de Wit,Iain B. McInnes,Maxime Dougados,Jette Primdahl,Dennis McGonagle,Daniel Aletaha,Andra Balanescu,Peter V. Balint,Heidi Bertheussen,Wolf-Henning Boehncke,Gerd R Burmester,Juan D. Cañete,Nemanja Damjanov,Tue Wenzel Kragstrup,Tore K Kvien,Robert Landewé,Rik Lories,Helena Marzo-Ortega,Denis Poddubnyy,Santiago Rodrigues Manica,Georg Schett,Douglas J. Veale,Filip Van den Bosch,Désirée van der Heijde,Josef S Smolen +27 more
TL;DR: The updated recommendations provide stakeholders with an updated consensus on the pharmacological management of PsA, based on a combination of evidence and expert opinion.
Journal ArticleDOI
Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force
Josef S. Smolen,Monika Schöls,Jürgen Braun,Maxime Dougados,Oliver FitzGerald,Dafna D. Gladman,Arthur Kavanaugh,Robert Landewé,Philip J. Mease,Joachim Sieper,Tanja Stamm,Maarten de Wit,Daniel Aletaha,Xenofon Baraliakos,Neil Betteridge,Filip Van den Bosch,Laura C. Coates,Paul Emery,Lianne S. Gensler,Laure Gossec,Philip S. Helliwell,Merryn Jongkees,Tore K Kvien,Robert D. Inman,Iain B. McInnes,Mara Maccarone,Pedro Machado,Anna Molto,Alexis Ogdie,Denis Poddubnyy,Christopher T. Ritchlin,Martin Rudwaleit,Adrian Tanew,Bing Thio,Douglas J. Veale,Kurt de Vlam,Désirée van der Heijde +36 more
TL;DR: There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA.